Skip to Content Skip to Search

Slovenia

Please select...

Disclosure of payments made to HCPs in Slovenia

As part of our goal to be one of the most innovative, best performing and trusted healthcare companies in the world, we seek to meet society’s evolving expectations, bring greater transparency to an already well-regulated industry, and strengthen our relationships with Healthcare Professionals (HCPs), and Healthcare Organisations (HCOs) for future collaboration.

Cooperation between pharmaceutical companies, regulators, HCPs, HCOs and patients, is essential for the sustainable improvement of healthcare. These relationships have helped deliver numerous innovative new medicines and changed the way many diseases impact on our lives. HCPs have always been and will always be, valuable partners for GSK. As experts in their field, they provide us with first hand scientific and medical knowledge and unique insights into patient care. This partnership is fundamental to the progression of medical science, helping to meet patient and public health needs.

Under the (EFPIA) Disclosure Code, from 2016 EFPIA member companies pledged to disclose the transfers of value they make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes, for example, sponsorship for travel and registration fees to attend medical congresses, HCP consultancy fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.

Transfer of value disclosure information is published annually (covering the previous year) on a public platform; either the company’s own website or, in some countries, a central platform combining data from different companies.

Our disclosures for Slovenia

The links below will take you to our disclosures for Slovenia in line with the EFPIA code and Forum, and to a note on the methodology used to set out the data in the report.

Year

Report

Methodological Note

2020

PDF

PDF

Previous year(s) 

  

2019

PDF

PDF

2018

PDF

PDF

For media enquiries, please contact: WW.CEEurope-media@gsk.com

Razkritje plačil zdravstvenim delavcem v Sloveniji

Del našega cilja, biti eno izmed najbolj inovativnih, uspešnih in zaupanja vrednih zdravstvenih podjetij na svetu, je prizadevanje, da uresničimo pričakovanja družbe, prinesemo večjo preglednost v že dobro urejene panoge in v prihodnjem sodelovanju okrepimo odnose z zdravstvenimi strokovnjaki (ZD) in zdravstvenimi organizacijami (ZO)..

Sodelovanje med farmacevtskimi družbami, regulatornimi organi, zdravstvenimi delavci (ZD), zdravstvenimi organizacijami (ZO) in bolniki je bistvenega pomena za trajnostno izboljšanje zdravstvenega varstva. Ti odnosi so pripomogli k zagotavljanju številnih inovativnih novih zdravil in spremenili način, kako mnoge bolezni vplivajo na naše življenje. Zdravstveni delavci so vedno bili in bodo tudi ostali dragoceni partnerji  GSK. Kot strokovnjaki na svojem področju nam nudijo znanstveno in medicinsko znanje ter edinstven vpogled v oskrbo pacientov. To partnerstvo je temeljnega pomena za napredovanje medicinske znanosti, ki prispeva k izpolnjevanju različnih potreb bolnikov in javnega zdravja.

Skladno s kodeksom EFPIA so se članice zavezale, da bodo od leta 2016 dalje javno razkrile  nakazila zdravstvenim delavcem in zdravstvenim organizacijam v zvezi z zdravili na recept, in sicer z individualnim poimenovanjem (le izjemoma agregirano). To vključuje na primer povrnitev pristojbin za registracijo in stroškov potovanj zdravstvenim delavcem za udeležbo na medicinskih kongresih, nadomestila zdravstvenim delavcem za  pripravo predavanj ali vodenj strokovnih sestankov in donacije zdravstvenim organizacijam. Nakazila zdravstvenim delavcem in zdravstvenim organizacijam s področja raziskav in razvoja so objavljena agregirano.

Informacije o razkritju nakazil  bodo objavljene letno (za preteklo leto) na javni platformi; bodisi na spletni strani posamezne družbe ali, v nekaterih državah, na skupni platformi, ki bo vsebovala podatke različnih družb.

Naše objave za Slovenijo

Spodnje povezave vas preusmerijo do naših objav za Slovenijo v skladu s kodeksom EFPIA in kodeksom Mednarodnega foruma znanstvenoraziskovalnih farmacevtskih družb (GIZ); tam boste našli tudi opombo o metodologiji, uporabljeni za pripravo podatkov v poročilu.

Leto

Poročilo

Metodološka opomba

2020

PDF

PDF

Prejšnje leto/
prejšnja leta

  

2019

PDF

PDF

2018

PDF

PDF


Novinarska vprašanja naslovite na WW.CEEurope-media@gsk.com

Back to top